Chronix Biomedical reports positive interim pancreatic cancer data

Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer. The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy1 compared to CA19-9, a commonly used biomarker.

By | June 14th, 2017|Chronix news|0 Comments

Chronix Biomedical is pleased to be a sponsor of the PCRT annual meeting

Chronix Biomedical

Chronix looks forward to working with this team of international pancreatic cancer experts.

By | June 2nd, 2017|Chronix news|0 Comments

Chronix at the ASCO 2017 Annual Meeting

Chronix Biomedical

This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.

By | June 2nd, 2017|Chronix news|0 Comments

Predicting Treatment Outcomes in Immunotherapy

Weiss, G. et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Genomic analysis of tissue malignancies is well recapitulated by tumor cell free DNA (cfDNA) using the power of Next Generation Sequencing (NGS).

By | May 14th, 2017|Peer-reviewed medical publications|0 Comments

Predicting Treatment Outcomes in Chemotherapy

Weiss, Glen J., et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research 76.14 Supplement (2016): 3138-3138.

Gains and losses of chromosomal regions – as a hallmark of cancer – have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.

By | May 13th, 2017|Peer-reviewed medical publications|0 Comments

Prostate Cancer Blood Test

Schütz, E., et al. Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer. Clinical Chemistry 2015; 61: 239-248.

Tumor-specific cell free DNA (cfDNA) present in serum and plasma provides a real-time, easily accessible surrogate. We demonstrated variations in the number of cfDNA sequences circulating in the serum of patients with prostate cancer compared with healthy controls.

By | May 12th, 2017|Peer-reviewed medical publications|0 Comments

Cohort Study in LiverTx

Schütz E. et al. Graft-Derived Cell-Free DNA – a Noninvasive Early Rejection and Graft Damage Marker in Liver Transplantation PlosMed (2017;) doi:10.1371/journal.pmed.1002286

Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker.

By | May 11th, 2017|Peer-reviewed medical publications|0 Comments

Rectal Cancer Treatment Outcome Predictions

Beck, J. et al. Comprehensive analyses of rectal cancer genomes to reveal copy number variations as potential predictor of induction therapy efficacy. J ClinOncol 32, 2014 (suppl; abstr e14549).

Genome profiling of individual tumors is provided by high-throughput sequencing and is about to enter routine clinical practice with impact on treatment decisions and tumor classification (NIH [2014] The Cancer Genome Atlas).

By | May 11th, 2017|Peer-reviewed medical publications|0 Comments

HPV Genotyping and Treatment Outcome Predictions

Urnovitz, HB et al. Detection of novel HPV mutations and chromosomal number imbalance (CNI) in laryngeal cancer using next-generation sequencing (NGS). J ClinOncol 32:5s, 2014 (suppl; abstr 6072).

The detection of novel HPV mutations and CNI analysis in a single NGS run on HPV-related diseases provides important information into viral-host dynamics while generating biomarkers that can be correlated with treatment outcomes.

By | May 10th, 2017|Peer-reviewed medical publications|0 Comments

Breast Cancer Liquid Biopsy Screening Test

Beck, J. et al. Cell-free DNA copy number variations as a marker for breast cancer in a large study cohort. J ClinOncol 31, 2013 (suppl; abstr 11013).

Using comparative massive parallel sequencing of cfDNA from cancer patients vs. controls, we were able to show that a 16-region model based on CNV, is useful to distinguish patients with breast cancer from matched controls.

By | May 9th, 2017|Peer-reviewed medical publications|0 Comments